Tech Company Financing Transactions

Tiburio Therapeutics Funding Round

Tiburio Therapeutics, operating out of Cambridge, secured $31 million from Alexandria Venture Investments, Longitude Capital Management and Lundbeckfond Ventures.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series A
Proceeds Purpose
Proceeds will fund the company's lead compound, TBR-760, through human proof-of-concept for the treatment of NFPA and further clinical assessment of TBR-065 as a treatment for rare endocrine diseases.

Company Information

Company Status
Private & Independent
Mailing Address
700 Technology Square 2nd Floor
Cambridge, MA 02139
Email Address
Tiburio is a clinical stage biopharmaceutical company dedicated to advancing novel treatments for rare neuroendocrine tumors and rare endocrine diseases where there is significant patient need.
Tiburio Therapeutics LinkedIn Company Profile
Social Media
Tiburio Therapeutics Company Twitter Account
Company News
Tiburio Therapeutics News
Tiburio Therapeutics on Facebook
Tiburio Therapeutics on YouTube

Management Team

Email & Social
Chief Executive Officer
Abraham Ceesay
  Abraham Ceesay LinkedIn Profile  Abraham Ceesay Twitter Account  Abraham Ceesay News  Abraham Ceesay on Facebook
Chief Medical Officer
Shi Foo
  Shi Foo LinkedIn Profile  Shi Foo Twitter Account  Shi Foo News  Shi Foo on Facebook



Browse more venture capital transactions:

Prev: 1/4/2019: Preemadonna venture capital transaction
Next: 1/4/2019: Cabaletta Bio venture capital transaction


Share this article


Where The Data Comes From

We report on every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary